Immune-modulation by epidermal growth factor receptor inhibitors: Implication on anti-tumor immunity in lung cancer

Jin S. Im, Amanda C. Herrmann, Chantale Bernatchez, Cara Haymaker, Jeffrey J. Molldrem, Waun Ki Hong, Roman Perez-Soler

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Skin toxicity is the most common toxicity caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors enhance the expression of antigen presenting molecules in affected skin keratinocytes, they may concurrently facilitate neo-antigen presentation in lung cancer tumor cells contributing to anti-tumor immunity. Here, we investigated the modulatory effect of the EGFR inhibitor, erlotinib on antigen presenting molecules and PD-L1, prominent immune checkpoint protein, of skin keratinocytes and lung cancer cell lines to delineate the link between EGFR signaling pathway inhibition and potential anti-tumor immunity. Erlotinib up-regulated MHC-I and MHC-II proteins on IFNã treated keratinocytes but abrogated IFNã-induced expression of PD-L1, suggesting the potential role of infiltrating autoreactive T cells in the damage of keratinocytes in affected skin. Interestingly, the surface expression of MHC-I, MHC-II, and PD-L1 was up-regulated in response to IFNã more often in lung cancer cell lines sensitive to erlotinib, but only expression of PD-L1 was inhibited by erlotinib. Further, erlotinib significantly increased T cell mediated cytotoxicity on lung cancer cells. Lastly, the analysis of gene expression dataset of 186 lung cancer cell lines from Cancer Cell Line Encyclopedia demonstrated that overexpression of PD-L1 was associated with sensitivity to erlotinib and higher expression of genes related to antigen presenting pathways and IFNã signaling pathway. Our findings suggest that the EGFR inhibitors can facilitate anti-tumor adaptive immune responses by breaking tolerance especially in EGFR driven lung cancer that are associated with overexpression of PD-L1 and genes related to antigen presentation and inflammation.

Original languageEnglish (US)
Article numbere0160004
JournalPLoS One
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

lung neoplasms
Epidermal Growth Factor Receptor
Tumors
Immunity
Lung Neoplasms
immunity
Cells
Modulation
Keratinocytes
keratinocytes
neoplasms
Skin
Antigens
Cell Line
cell lines
Neoplasms
T-cells
Antigen Presentation
antigen presentation
Toxicity

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Immune-modulation by epidermal growth factor receptor inhibitors : Implication on anti-tumor immunity in lung cancer. / Im, Jin S.; Herrmann, Amanda C.; Bernatchez, Chantale; Haymaker, Cara; Molldrem, Jeffrey J.; Hong, Waun Ki; Perez-Soler, Roman.

In: PLoS One, Vol. 11, No. 7, e0160004, 01.07.2016.

Research output: Contribution to journalArticle

Im, Jin S. ; Herrmann, Amanda C. ; Bernatchez, Chantale ; Haymaker, Cara ; Molldrem, Jeffrey J. ; Hong, Waun Ki ; Perez-Soler, Roman. / Immune-modulation by epidermal growth factor receptor inhibitors : Implication on anti-tumor immunity in lung cancer. In: PLoS One. 2016 ; Vol. 11, No. 7.
@article{5c61e564ff484e9b95a23bd3f1cf8115,
title = "Immune-modulation by epidermal growth factor receptor inhibitors: Implication on anti-tumor immunity in lung cancer",
abstract = "Skin toxicity is the most common toxicity caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors enhance the expression of antigen presenting molecules in affected skin keratinocytes, they may concurrently facilitate neo-antigen presentation in lung cancer tumor cells contributing to anti-tumor immunity. Here, we investigated the modulatory effect of the EGFR inhibitor, erlotinib on antigen presenting molecules and PD-L1, prominent immune checkpoint protein, of skin keratinocytes and lung cancer cell lines to delineate the link between EGFR signaling pathway inhibition and potential anti-tumor immunity. Erlotinib up-regulated MHC-I and MHC-II proteins on IFN{\~a} treated keratinocytes but abrogated IFN{\~a}-induced expression of PD-L1, suggesting the potential role of infiltrating autoreactive T cells in the damage of keratinocytes in affected skin. Interestingly, the surface expression of MHC-I, MHC-II, and PD-L1 was up-regulated in response to IFN{\~a} more often in lung cancer cell lines sensitive to erlotinib, but only expression of PD-L1 was inhibited by erlotinib. Further, erlotinib significantly increased T cell mediated cytotoxicity on lung cancer cells. Lastly, the analysis of gene expression dataset of 186 lung cancer cell lines from Cancer Cell Line Encyclopedia demonstrated that overexpression of PD-L1 was associated with sensitivity to erlotinib and higher expression of genes related to antigen presenting pathways and IFN{\~a} signaling pathway. Our findings suggest that the EGFR inhibitors can facilitate anti-tumor adaptive immune responses by breaking tolerance especially in EGFR driven lung cancer that are associated with overexpression of PD-L1 and genes related to antigen presentation and inflammation.",
author = "Im, {Jin S.} and Herrmann, {Amanda C.} and Chantale Bernatchez and Cara Haymaker and Molldrem, {Jeffrey J.} and Hong, {Waun Ki} and Roman Perez-Soler",
year = "2016",
month = "7",
day = "1",
doi = "10.1371/journal.pone.0160004",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Immune-modulation by epidermal growth factor receptor inhibitors

T2 - Implication on anti-tumor immunity in lung cancer

AU - Im, Jin S.

AU - Herrmann, Amanda C.

AU - Bernatchez, Chantale

AU - Haymaker, Cara

AU - Molldrem, Jeffrey J.

AU - Hong, Waun Ki

AU - Perez-Soler, Roman

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Skin toxicity is the most common toxicity caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors enhance the expression of antigen presenting molecules in affected skin keratinocytes, they may concurrently facilitate neo-antigen presentation in lung cancer tumor cells contributing to anti-tumor immunity. Here, we investigated the modulatory effect of the EGFR inhibitor, erlotinib on antigen presenting molecules and PD-L1, prominent immune checkpoint protein, of skin keratinocytes and lung cancer cell lines to delineate the link between EGFR signaling pathway inhibition and potential anti-tumor immunity. Erlotinib up-regulated MHC-I and MHC-II proteins on IFNã treated keratinocytes but abrogated IFNã-induced expression of PD-L1, suggesting the potential role of infiltrating autoreactive T cells in the damage of keratinocytes in affected skin. Interestingly, the surface expression of MHC-I, MHC-II, and PD-L1 was up-regulated in response to IFNã more often in lung cancer cell lines sensitive to erlotinib, but only expression of PD-L1 was inhibited by erlotinib. Further, erlotinib significantly increased T cell mediated cytotoxicity on lung cancer cells. Lastly, the analysis of gene expression dataset of 186 lung cancer cell lines from Cancer Cell Line Encyclopedia demonstrated that overexpression of PD-L1 was associated with sensitivity to erlotinib and higher expression of genes related to antigen presenting pathways and IFNã signaling pathway. Our findings suggest that the EGFR inhibitors can facilitate anti-tumor adaptive immune responses by breaking tolerance especially in EGFR driven lung cancer that are associated with overexpression of PD-L1 and genes related to antigen presentation and inflammation.

AB - Skin toxicity is the most common toxicity caused by Epidermal Growth Factor Receptor (EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors enhance the expression of antigen presenting molecules in affected skin keratinocytes, they may concurrently facilitate neo-antigen presentation in lung cancer tumor cells contributing to anti-tumor immunity. Here, we investigated the modulatory effect of the EGFR inhibitor, erlotinib on antigen presenting molecules and PD-L1, prominent immune checkpoint protein, of skin keratinocytes and lung cancer cell lines to delineate the link between EGFR signaling pathway inhibition and potential anti-tumor immunity. Erlotinib up-regulated MHC-I and MHC-II proteins on IFNã treated keratinocytes but abrogated IFNã-induced expression of PD-L1, suggesting the potential role of infiltrating autoreactive T cells in the damage of keratinocytes in affected skin. Interestingly, the surface expression of MHC-I, MHC-II, and PD-L1 was up-regulated in response to IFNã more often in lung cancer cell lines sensitive to erlotinib, but only expression of PD-L1 was inhibited by erlotinib. Further, erlotinib significantly increased T cell mediated cytotoxicity on lung cancer cells. Lastly, the analysis of gene expression dataset of 186 lung cancer cell lines from Cancer Cell Line Encyclopedia demonstrated that overexpression of PD-L1 was associated with sensitivity to erlotinib and higher expression of genes related to antigen presenting pathways and IFNã signaling pathway. Our findings suggest that the EGFR inhibitors can facilitate anti-tumor adaptive immune responses by breaking tolerance especially in EGFR driven lung cancer that are associated with overexpression of PD-L1 and genes related to antigen presentation and inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84982766646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982766646&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0160004

DO - 10.1371/journal.pone.0160004

M3 - Article

C2 - 27467256

AN - SCOPUS:84982766646

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0160004

ER -